Drugs / CD19 CAR-T
Trials 21
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-03-16 | HCW Biologics | Results HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances hcwbiologics.com ↗
In experimental models, human CAR-T cells manufactured using HCW9206 showed strong anti-tumor activity in leukemia and enhanced antiviral potency in HIV suggesting potential for curative outcomes |
| 2025-10-25 | Novartis Pharmaceuticals | Results Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases novartis.com ↗
Biomarker data from an open-label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a rapidly manufactured CD19 CAR-T therapy) suggest reset of the B Cell compartment in severe refractory SLE |
| 2022-01-18 | CASI pharmaceuticals, Inc. | Regulatory CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA issuerdirect.com ↗ |
| 2020-12-23 | CASI pharmaceuticals, Inc. | Regulatory CASI Pharmaceuticals Announces CNCT19 (CD19 CAR-T) Receives China Breakthrough Therapy Designation issuerdirect.com ↗
The Breakthrough Designation for CNCT19 was granted based on initial data from the ongoing single arm, open-label, non-randomized, dose-escalation, Phase I study designed to determine the safety and efficacy of CNCT19 in B-ALL. |
| 2019-12-03 | CASI pharmaceuticals, Inc. | Regulatory CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications issuerdirect.com ↗
CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications |
| 2019-09-16 | CASI pharmaceuticals, Inc. | Regulatory China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product issuerdirect.com ↗ |
| 2019-09-11 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Results Gracell Announces Interim Readout of Investigation for First-in-class FasT CAR-19 in patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and Extension in Use of FasT CAR to Other Immune Cell Programs gracellbio.com ↗
The study shows a high response rate, with 23 of 24 treated patients achieving complete remission and 21 of 24 treated patients achieving undetectable minimal residual disease on 28 days of follow-up |
| 2019-06-20 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Results Gracell Data on Multi-center Investigation of FasT CAR-19 Therapy Shows Positive First Impact in Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia gracellbio.com ↗
The customized treatment which genetically modifies patient"s T-cells to express CD19-specific chimeric antigen receptor (CAR), showed a clinically meaningful and positive result in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). |
All press releases naming this drug 10 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19 CAR-T | “This study is a single center, open label exploratory clinical trial aimed at evaluating the safety and efficacy of universal CD19 CAR-T therapy in subjects with autoimmune diseases.” NCT06983964 ↗21“Anti-CD19 CAR expressing T cells (CD19-CAR-T) will be expanded using a medium containing autologous plasma.” NCT02134262 ↗ “Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL” NCT03407859 ↗ “CD19 CAR-T” NCT05618041 ↗ |
| Known as | Anti-CD19 CAR expressing T cells | “Anti-CD19 CAR expressing T cells (CD19-CAR-T) will be expanded using a medium containing autologous plasma.” NCT02134262 ↗ |
| Action | Deplete | “This kind of engineered T cells gains the ability to recognize antigen specific tumor cells and initiate the killing process” NCT03232619 ↗ |
| Modality | Cell therapy | “autologous T cells genetically modified to express anti-CD19 Chimeric Antigen Receptor” NCT02134262 ↗ |
| Route | Intravenous | “infusions of CD19CART cells into the vein” NCT02813837 ↗ |
| Target | CD19 | “CD19 targeted chimeric antigen receptor T cells therapy” NCT02813837 ↗ |